AAPS PharmSciTech

, Volume 13, Issue 3, pp 760–771 | Cite as

Miconazole Nitrate Oral Disintegrating Tablets: In Vivo Performance and Stability Study

  • Tarek A. AhmedEmail author
  • Khalid M. El-Say
  • Maged F. Mahmoud
  • Ahmed M. Samy
  • Alia A. Badawi
Research Article


The interest in and need for formulating miconazole nitrate (MN), a broad-spectrum antifungal, as an oral disintegrating tablet for treatment of some forms of candidiasis have increased. Formulation of MN in this dosage form will be more advantageous, producing dual effect: local in the buccal cavity and systemic with rapid absorption. Four formulations were prepared utilizing the foam granulation technique. The prepared tablets were characterized by measuring the weight uniformity, thickness, tensile strength, friability, and drug content. In addition, tablet disintegration time, in vitro dissolution, and in vivo disintegration time were also evaluated. Stability testing for the prepared tablets under stress and accelerated conditions in two different packs were investigated. Each pack was incubated at two different elevated temperature and relative humidity (RH), namely 40 ± 2°C/75 ± 5% RH and 50 ± 2°C/75 ± 5% RH. The purpose of the study is to monitor any degradation reactions which will help to predict the shelf life of the product under the defined storage conditions. Finally, in vivo study was performed on the most stable formula to determine its pharmacokinetic parameters. The results revealed that all the prepared tablets showed acceptable tablet characteristics and were stable under the tested conditions. The most stable formula was that containing magnesium stearate as lubricant, hydrophobic Aerosil R972 as glidant, low urea content, mannitol/microcrystalline cellulose ratio 2:1, and 9% Plasdone XL100 as superdisintegrant. The in vivo results revealed that the tested formula showed rapid absorption compared to the physical blend (t max were 1 and 4 h, respectively), while the extent of absorption was almost the same.


accelerated stability testing bioavailability foam granulation technique miconazole nitrate oral disintegrating tablet 



The authors highly appreciated the cooperation of DEEF Pharmaceutical Industries Company for giving the research team the permission to use the foam granulation machine.


  1. 1.
    Himanshu KS, Tarashankar B, Jalaram HT, Chirag AP. Recent advances in granulation technology. Int J Pharm Sci Rev Res. 2010;5(3):Article-008.Google Scholar
  2. 2.
    Sandler N, Lammens RF. Pneumatic dry granulation: potential to improve roller compaction technology in drug manufacture. Expert Opin Drug Deliv. 2011;8(2):225–36.PubMedCrossRefGoogle Scholar
  3. 3.
    Powder pro (2012) Accessed 8 Apr 2012.
  4. 4.
    Ochoa L, Igartua M, Hernández RM, Gascón AR, Pedraz JL. Preparation of sustained release hydrophilic matrices by melt granulation in a high-shear mixer. J Pharm Pharm Sci. 2005;8(2):132–40.PubMedGoogle Scholar
  5. 5.
    Rodriguez L, Cavallari C, Passerini N, Albertini B, González-Rodríguez M, Fini A. Preparation and characterization by morphological analysis of diclofenac/PEG 4000 granules obtained using three different techniques. Int J Pharm. 2002;242(1–2):285–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Ismat U, Jennifer W, Shih-Ying C, Gary JW, Nemichand BJ, San K. Moisture activated dry granulation—part I: a guide to excipient and equipment selection and formulation development. Pharm Technol. 2009;33(11):62–70.Google Scholar
  7. 7.
    Lin HL, Ho HO, Chen CC, Yeh TS, Sheu MT. Process and formulation characterizations of the thermal adhesion granulation (TAG) process for improving granular properties. Int J Pharm. 2008;357(1–2):206–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Paul J, Shesky R, Colin K. New foam binder technology from Dow improves granulation process. Pharm Can. 2006; 19–22.Google Scholar
  9. 9.
    Bouckaert S, Remon JP. In vitro bioadhesion of a buccal, miconazole slow release tablets. J Pharm Pharmacol. 1993;45:504–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Minghetti P, Cilurzo F, Casiraghi A, Molla FA, Montanari L. Dermal patches for the controlled release of miconazole: influence of the drug concentration on the technological characteristics. Drug Dev Ind Pharm. 1999;25:679–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Mandal TK. Swelling-controlled release system for the vaginal delivery of miconazole. Eur J Pharm Biopharm. 2000;50:337–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Pedersen M, Rassing MR. Miconazole chewing gum as a drug delivery system: test of release promoting additives. Drug Dev Ind Pharm. 1991;17:411–20.CrossRefGoogle Scholar
  13. 13.
    Bouckaert S, Schautteet H, Lefebvre RA, Remon JP, van Clooster R. Comparison of salivary miconazole concentrations after administration of a bioadhesive slow-release buccal tablet and an oral gel. Eur J Clin Phamacol. 1992;43:137–40.CrossRefGoogle Scholar
  14. 14.
    ICH. Stability testing of new drug substances and products. Geneva: International Conference on Harmonization, IFPMA; 1993.Google Scholar
  15. 15.
    ICH. Impurities in new drug products. Geneva: International Conference on Harmonization, IFPMA; 1996.Google Scholar
  16. 16.
    Hui Y, Huang NH, Ebbert L, Bina H, Chiang A, Maples C, Pritt M, Kern T, Patel N. Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs. J Pharmacol Toxicol Methods. 2007;56:256–64.PubMedCrossRefGoogle Scholar
  17. 17.
    EMEA, The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on quality of modified release products. A: oral dosage forms. B: transdermal dosage forms, Section I (quality). 1999. CPMP/QWP/604/96, 1–15.Google Scholar
  18. 18.
    USP 28, the United States Pharmacopoeia, 28th Revision. Rockville, MD: Pharmacopoeial Convention, Inc. 2005.Google Scholar
  19. 19.
    Burgess DJ, Crommelin DJA, Hussain AS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS PharmSci. 2004;6(1):Article 11.CrossRefGoogle Scholar
  20. 20.
    Harshal AP, Priscilla MD. Development and evaluation of herbal laxative granules. J Chem Pharm Res. 2011;3(3):646–50.Google Scholar
  21. 21.
    Aulton ME. Pharmaceutics: the science of dosage form design. 2nd ed. New York: Churchill Livingstone; 2002. p. 154–5.Google Scholar
  22. 22.
    Wells J. Pharmaceutical preformulation. In: Aulton ME, editor. Pharmaceutics the science of dosage form design. 2nd ed. Edinburgh: Churchill Livingstone; 2003. p. 133–4.Google Scholar
  23. 23.
    Haririan I, Newton JM. Tensile strength of circular flat and convex-faced avicel PH102 tablets. Daru. 1999;7(3):36–9.Google Scholar
  24. 24.
    USFDA. Dissolution methods database. 2010. Accessed on 15 Jun 2010.
  25. 25.
    Okuda Y, Irisawa Y, Okimoto K, Osawa T, Yamashita S. A new formulation for orally disintegrating tablets using a suspension spray-coating method. Int J Pharm. 2009;382:80–7.PubMedCrossRefGoogle Scholar
  26. 26.
    USFDA. Bioequivalence guidelines. 2010. Accessed 15 Jun 2010.
  27. 27.
    Kobylifiska M, Kobylifiska K, Sobik B. High-performance liquid chromatographic analysis for the determination of miconazole in human plasma using solid phase extraction. J Chromatogr B Biomed Appl. 1996;685:191–5.CrossRefGoogle Scholar
  28. 28.
    Sheskey P, Keary C, Clark D, Balwinski K. Scale up formulae of foam granulation technology-high shear. Pharm Technol. 2007;31(4):94–9.Google Scholar
  29. 29.
    Barillaro V, Bertholet P, Sandrine HH. Effect of acidic ternary compounds on the formation of miconazole/cyclodextrin inclusion complexes by means of supercritical carbon dioxide. J Pharm Pharm Sci. 2004;7(3):378–88.PubMedGoogle Scholar
  30. 30.
    Barillaro V, Dive G, Bertholet P, Evrard B, Delattre L, Frederich M, Ziemons E, Piel G. Theoretical and experimental investigations of organic acids/ cyclodextrin complexes and their consequences upon the formation of miconazole/previous termcyclodextrin/acid ternary inclusion complexes. Int J Pharm. 2007;342:152–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Yoshinari T, Forbes RT, York P, Kawashima Y. The improved compaction properties of mannitol after a moisture-induced polymorphic transition. Int J Pharm. 2003;258:121–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Nie X. Heat and moisture migration within a porous urea particle bed. PhD thesis, University of Saskatchewan, 2010; p. 8–9.Google Scholar
  33. 33.
    USP, the United States Pharmacopoeia. 34th edn., Rockville, MD: Pharmacopoeial Convention, Inc. 2011.Google Scholar
  34. 34.
    Lerk CF, Lagas M, Fell JT, Nauta P. Effect of hydrophilization of hydrophobic drugs on release rate from capsules. J Pharm Sci. 1978;67(7):935–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Jafari MR, Danti AG, Ahmed I. Comparison of polyethylene glycol, polyvinylpyrrolidone and urea as excipients for solid dispersion systems of MN. Int J Pharm. 1988;48:207–15.CrossRefGoogle Scholar
  36. 36.
    ICH. International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use, by the ICH Steering Committee, version 2, 2005.Google Scholar
  37. 37.
    The European Pharmacopoeia (Ph.Eur.). 6th ed., Strasbourg, France: European Directorate for the Quality of Medicines, Council of Europe. 2010.Google Scholar
  38. 38.
    Faroongsarng D, Peck GE. Thermal porosity analysis of croscarmellose sodium and sodium starch glycolate by differential scanning calorimetry. AAPS Pharma Sci Tech. 2003;4:E67.Google Scholar
  39. 39.
    Stubberud L, Arwidsson HG, Graffner C. Water–solid interactions: a technique for studying moisture sorption/ desorption. Int J Pharm. 1995;114:55–64.CrossRefGoogle Scholar
  40. 40.
    Rowe RC, Shesky PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 196–8.Google Scholar
  41. 41.
    Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm. 2006;317:61–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Barillaro V, Bertholet P, Sandrine HH. Effect of acidic ternary compounds on the formation of miconazole/cyclodextrin inclusion complexes by means of supercritical carbon dioxide. J Pharm Sci. 2004;7(3):378–88.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2012

Authors and Affiliations

  • Tarek A. Ahmed
    • 1
    • 2
    Email author
  • Khalid M. El-Say
    • 1
    • 2
  • Maged F. Mahmoud
    • 2
  • Ahmed M. Samy
    • 2
  • Alia A. Badawi
    • 3
  1. 1.Department of Pharmaceutics and Industrial Pharmacy, Faculty of PharmacyKing Abdulaziz UniversityJeddahKingdom of Saudi Arabia
  2. 2.Department of Pharmaceutics and Industrial Pharmacy, Faculty of PharmacyAl-Azhar universityCairoEgypt
  3. 3.Department of Pharmaceutics and Industrial Pharmacy, Faculty of PharmacyCairo UniversityCairoEgypt

Personalised recommendations